Latest News

No gain with higher dose of glatiramer acetate

 

A higher dose of glatiramer acetate appears to be well tolerated but does not provide improved efficacy over standard dosing, according to the results of the FORTE study (Comi et al. Ann Neurol 2011; 69: 75-82).

Read More

TOPICS:

PD progression, QOL impairments less in females

 

Disease progression in patients newly-diagnosed with Parkinson’s disease is less pronounced in females but more severe in older subjects, according to data from the Co-morbidity and Ageing in Rehabilitation Patients; the influence on Activities (CARPA) study group (Post et al. Mov Disor 2011; 26: 449-456).

Read More

TOPICS: